Asia Spotlight: China's Health Ministry To Expand Corruption Probe In Pharma
Executive Summary
On the second Monday of each month, "The Pink Sheet" provides exclusive news and commentary on the Asia biopharma market from the editors of its affiliated online publication, PharmAsia News. Register at 1http://pharmasianews.elsevierbi.com/PAN_Trial_LP.html for a free trial.
You may also be interested in...
Chinese SFDA Deputy Director Under Investigation For Corruption
BEIJING - A deputy director of China's State FDA is under investigation by the Communist Party's top anti-corruption commission, which could have broad ramifications for the drug agency's daily operations
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials